Nuwellis, Inc. (NASDAQ:NUWE) Sees Significant Growth in Short Interest

Nuwellis, Inc. (NASDAQ:NUWE – Get Free Report) was the target of a significant growth in short interest in the month of October. As of October 30th, there was short interest totaling 195,586 shares, a growth of 118.9% from the October 15th total of 89,357 shares. Approximately 36.8% of the company’s shares are sold short. Based on an average daily trading volume, of 3,723,204 shares, the short-interest ratio is presently 0.1 days.

Nuwellis Price Performance

Shares of NASDAQ NUWE traded down $0.18 during midday trading on Monday, hitting $4.71. 4,439 shares of the company’s stock were exchanged, compared to its average volume of 337,937. The firm has a market cap of $2.55 million, a P/E ratio of -0.00 and a beta of 0.03. Nuwellis has a twelve month low of $2.52 and a twelve month high of $1,556.07. The stock’s 50 day moving average price is $6.03 and its 200-day moving average price is $206.53.

Nuwellis (NASDAQ:NUWE – Get Free Report) last posted its quarterly earnings data on Thursday, November 12th. The company reported ($5.81) earnings per share for the quarter, topping the consensus estimate of ($122.85) by $117.04. Nuwellis had a negative net margin of 150.50% and a negative return on equity of 414.75%. The business had revenue of $2.21 million during the quarter, compared to the consensus estimate of $2.50 million.

Analyst Upgrades and Downgrades

A number of brokerages have issued reports on NUWE. Weiss Ratings reissued a “sell (e+)” rating on shares of Nuwellis in a research note on Monday, September 21st. Wall Street Zen lowered shares of Nuwellis from a “hold” rating to a “sell” rating in a report on Saturday. One equities research analyst has rated the stock with a Sell rating. Based on data from MarketBeat.com, the stock presently has a consensus rating of “Sell”.

Check Out Our Latest Research Report on NUWE

Nuwellis Company Profile

(Get Free Report)

Nuwellis, Inc. is a medical technology company focused on fluid management for patients with fluid overload. The company develops and markets the Aquadex SmartFlow system, which uses ultrafiltration to remove excess fluid and is used by healthcare professionals in hospital settings. Aquadex includes a device and disposable components designed to support controlled fluid removal. It is intended for use in adults and children with fluid overload, including patients who may not respond adequately to diuretic therapy.

Further Reading

Receive News & Ratings for Nuwellis Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Nuwellis and related companies with MarketBeat.com's FREE daily email newsletter.